 TRACON Pharmaceuticals NASDAQ:TCON Inc announced that it has submitted an application to initiate a trial combining a new drug to be taken in combination with two other medications by patients with various types of tumours. Tracon said it has filed an investigational new drug IND application to the US Food and Drug Administration FDA for the initiation of a phase one and two clinical study of CTLA-4 antibody YH001 in combination with envafolimab and doxorubicin for front-line patients with sarcomas, including those who have not previously received therapy. 